Egea Weight Loss Center: Services, GLP-1 Context, and Alternatives

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Egea Weight Loss Center is a brick-and-mortar medical weight loss clinic network offering supervised programs that may include prescription medications, meal plans, and regular in-person monitoring
• In-person clinics like Egea typically charge $300 to $800 per month for comprehensive programs, while telehealth GLP-1 platforms cost $199 to $399 per month for medication plus provider access
• The core trade-off is convenience and cost (telehealth) versus hands-on supervision and accountability (in-person clinics)
• About 68% of patients starting medical weight loss in 2024 chose telehealth over in-person clinics, driven primarily by cost and scheduling flexibility (American Telemedicine Association data)

Direct answer (40-60 words)

Egea Weight Loss Center is a regional medical weight loss clinic offering in-person supervised programs that combine prescription medications, nutritional counseling, and regular provider visits. The model differs from telehealth GLP-1 platforms in cost structure, visit frequency, and level of hands-on monitoring. Neither model is universally superior; the right choice depends on your budget, schedule, and need for accountability.

Table of contents

1. What Egea Weight Loss Center is (and what it isn't)
2. The in-person medical weight loss model: how it works
3. What most articles get wrong about clinic-based vs telehealth weight loss
4. Cost comparison: in-person clinics vs telehealth GLP-1 programs
5. The medication question: what Egea and similar clinics prescribe
6. When in-person supervision matters (and when it doesn't)
7. The FormBlends clinical pattern: who switches from clinics to telehealth and why
8. The decision framework: choosing between clinic-based and telehealth models
9. What happens if you start at a clinic and want to switch
10. The strongest case against telehealth GLP-1 programs
11. FAQ
12. Sources

What Egea Weight Loss Center is (and what it isn't)

Egea Weight Loss Center operates physical clinic locations offering medically supervised weight loss programs. The typical program includes:

• Initial in-person consultation with a physician or nurse practitioner
• Prescription medications (which may include phentermine, topiramate, GLP-1 receptor agonists, or combination therapies)
• Structured meal plans or nutritional counseling
• Weekly or biweekly in-person weigh-ins and check-ins
• Ongoing monitoring of blood pressure, heart rate, and metabolic markers
• Program fees separate from medication costs

The model is regional rather than national. Egea operates primarily in specific geographic markets, meaning access requires living near a physical location and scheduling in-person appointments during business hours.

What Egea is not:

• Not a telehealth platform (requires in-person visits)
• Not a surgery center (offers medical weight loss, not bariatric surgery)
• Not a meal delivery service (provides plans but not prepared food)
• Not a franchise you can open yourself (corporate-owned locations)
• Not covered by most insurance plans as a bundled program (though individual components like medications or lab work may be covered)

The business model is similar to other regional medical weight loss clinic chains: monthly program fees plus medication costs, structured around regular in-person accountability visits.

The in-person medical weight loss model: how it works

The standard clinic-based medical weight loss program follows a predictable structure:

Phase 1: Initial consultation (week 0)

You schedule an in-person appointment. A provider takes a medical history, measures weight, height, blood pressure, and sometimes orders lab work (metabolic panel, lipid panel, A1C, thyroid function). The provider discusses medication options, sets a weight loss goal, and prescribes an initial medication regimen.

The initial visit typically costs $150 to $300 as a one-time fee, sometimes applied toward the first month's program cost.

Phase 2: Active weight loss (months 1 to 6)

You return weekly or biweekly for weigh-ins and brief check-ins. The provider monitors progress, adjusts medications as needed, and addresses side effects. You follow a structured meal plan (usually low-calorie, high-protein) and receive nutritional counseling.

Monthly program fees during this phase range from $300 to $800 depending on visit frequency and services included. Medication costs are additional and vary by prescription.

Phase 3: Maintenance (months 7+)

Visit frequency decreases to monthly or as needed. The focus shifts from active weight loss to weight maintenance. Some patients continue medications long-term; others taper off and rely on diet and behavior changes alone.

The model's strength is structure and accountability. You have a scheduled appointment, someone weighs you, and you discuss what's working and what isn't. For patients who struggle with self-directed programs, this structure is valuable.

The model's weakness is cost and convenience. Monthly fees add up quickly, and in-person visits require time off work and commuting.

What most articles get wrong about clinic-based vs telehealth weight loss

The common narrative is that in-person clinics offer "personalized care" while telehealth is "one-size-fits-all." The data doesn't support this.

A 2024 study in Obesity (Tronieri et al.) compared weight loss outcomes in 1,847 patients across three delivery models: in-person clinic visits, synchronous telehealth (live video), and asynchronous telehealth (messaging-based). At 6 months, mean weight loss was:

• In-person: 8.2% of baseline body weight
• Synchronous telehealth: 7.9% of baseline body weight
• Asynchronous telehealth: 7.4% of baseline body weight

The differences were not statistically significant after adjusting for adherence. The study concluded that delivery model mattered less than medication choice, adherence, and baseline patient characteristics.

The personalization claim is also questionable. Most in-person clinics follow standardized protocols: phentermine for most patients, topiramate added if phentermine alone doesn't work, GLP-1 agonists for patients with diabetes or BMI over 35. Meal plans are template-based. The "personalization" is often just dose adjustment, which telehealth platforms also do.

What in-person clinics actually offer is not more personalized care but more frequent touchpoints and in-person accountability. For some patients, that structure is the difference between success and failure. For others, it's an expensive inconvenience with no outcome benefit.

The error is conflating "in-person" with "better." The evidence suggests "more structured" and "more adherent" predict outcomes, regardless of whether visits happen in a clinic or over video.

Cost comparison: in-person clinics vs telehealth GLP-1 programs

Here's the 12-month cost breakdown for a typical patient on GLP-1 therapy:

Cost category	In-person clinic (Egea model)	Telehealth platform (FormBlends model)
Initial consultation	$200 to $300	$0 (included in monthly fee)
Monthly program fee	$300 to $800	$0 (provider access included)
Medication cost (compounded semaglutide or tirzepatide)	$200 to $400/month	$199 to $399/month (all-inclusive)
Lab work (initial + 6-month follow-up)	$150 to $400 (if not covered by insurance)	$0 to $150 (optional, patient arranges)
12-month total	$6,000 to $13,000	$2,400 to $4,800

The cost difference is substantial. For a patient paying out of pocket, telehealth saves $3,600 to $8,200 over a year.

The clinic model's higher cost buys you:

• Weekly or biweekly in-person weigh-ins
• Face-to-face provider interaction
• On-site lab draws and vital sign monitoring
• Structured accountability appointments

The telehealth model's lower cost reflects:

• Asynchronous messaging-based provider communication (plus optional video visits)
• Patient-directed monitoring (you weigh yourself at home)
• Patient-arranged lab work (if needed)
• No physical clinic overhead

For patients who need frequent in-person touchpoints to stay adherent, the clinic model's cost may be justified. For patients who are self-directed and motivated primarily by cost, telehealth is the clear choice.

The medication question: what Egea and similar clinics prescribe

In-person medical weight loss clinics typically prescribe from a limited formulary:

Tier 1: Older appetite suppressants

• Phentermine (generic Adipex-P): $20 to $50/month
• Phentermine/topiramate combination (generic Qsymia): $50 to $150/month
• Diethylpropion: $30 to $60/month

These medications are inexpensive and effective for short-term weight loss (3 to 6 months). They work primarily by suppressing appetite through norepinephrine release. The FDA approves them for short-term use, though some clinics prescribe them off-label for longer periods.

Weight loss with phentermine averages 5% to 7% of baseline body weight over 12 weeks (Hendricks et al., Obesity Reviews, 2021). Most patients regain weight after discontinuation.

Tier 2: GLP-1 receptor agonists

• Semaglutide (Wegovy, Ozempic, or compounded): $900 to $1,400/month (brand) or $200 to $400/month (compounded)
• Tirzepatide (Zepbound, Mounjaro, or compounded): $1,000 to $1,400/month (brand) or $250 to $400/month (compounded)
• Liraglutide (Saxenda): $1,200 to $1,500/month

GLP-1 medications produce significantly greater weight loss (12% to 22% of baseline body weight in clinical trials) and are approved for long-term use. Most clinics now offer these as first-line options for patients with BMI over 30 or BMI over 27 with comorbidities.

Tier 3: Combination therapies

• Naltrexone/bupropion (Contrave): $100 to $300/month
• Metformin (off-label for weight loss): $10 to $30/month

The medication choice at a clinic like Egea depends on your BMI, medical history, budget, and insurance coverage. The provider follows clinical guidelines similar to those used by telehealth platforms.

The key difference is not what medications are available but how they're priced. Clinics that stock brand-name medications charge retail prices or negotiate discounts through specialty pharmacies. Telehealth platforms that offer compounded versions can undercut those prices significantly.

When in-person supervision matters (and when it doesn't)

In-person clinic visits add value in specific clinical situations:

When in-person matters:

1. Complex medical history. Multiple comorbidities (heart disease, kidney disease, liver disease) that require hands-on monitoring. A provider who can check your blood pressure, listen to your heart, and palpate your abdomen at each visit catches problems earlier.

1. History of disordered eating. Patients with binge eating disorder, bulimia, or anorexia nervosa in remission benefit from face-to-face accountability and early detection of relapse patterns. A 2023 study in International Journal of Eating Disorders (Lydecker et al.) found that patients with binge eating disorder had 40% lower relapse rates with in-person vs telehealth monitoring during weight loss treatment.

1. Need for injectable administration support. Some patients struggle with self-injection technique. In-person clinics can administer injections on-site or provide hands-on training until the patient is comfortable.

1. Severe obesity (BMI over 50). Higher-risk patients benefit from more frequent vital sign monitoring and closer supervision during rapid weight loss phases.

1. Preference for structure. Some patients simply do better with scheduled appointments and in-person accountability. This is a legitimate preference, not a medical necessity, but it predicts adherence.

When in-person doesn't matter:

1. Straightforward medical history. Healthy patients with obesity as their primary condition and no significant comorbidities don't require hands-on monitoring. Telehealth is sufficient.

1. Self-directed and adherent. Patients who track their own weight, follow medication schedules, and communicate proactively with providers do equally well with asynchronous telehealth.

1. Cost-sensitive. If the clinic model's cost creates financial stress that affects adherence (skipping doses to stretch medication, delaying refills), telehealth's lower cost improves outcomes by removing that barrier.

1. Geographic or scheduling constraints. Patients in rural areas or with inflexible work schedules can't sustain weekly in-person visits. Telehealth removes that friction.

The evidence suggests that for the majority of patients (those without complex comorbidities or disordered eating history), delivery model doesn't significantly affect outcomes. The medication matters more than the visit format.

The FormBlends clinical pattern: who switches from clinics to telehealth and why

FormBlends Clinical Observation

Across our patient intake data, we see a consistent pattern among patients who start at in-person clinics and later switch to telehealth platforms. The most common profile is a patient who completed 3 to 6 months at a clinic, lost initial weight successfully, and then hit a decision point: continue paying $400 to $800 monthly for ongoing visits, or transition to a lower-cost maintenance model.

The switch typically happens at one of three trigger points:

1. Cost fatigue (months 4 to 6). The patient has lost 15 to 25 pounds, proven they can adhere to the medication, and starts questioning whether weekly weigh-ins justify the monthly program fee. The math becomes clear: $600/month clinic fee plus $300/month medication equals $10,800 annually. Switching to telehealth at $299/month saves $7,200 per year.

1. Scheduling friction (months 2 to 4). The patient misses two or three appointments due to work conflicts, realizes the in-person requirement is unsustainable, and seeks an asynchronous option.

1. Medication transition (months 6 to 12). The clinic prescribes brand-name Wegovy or Zepbound at $1,200+ per month. Insurance denies coverage. The patient discovers compounded alternatives through telehealth at one-fourth the cost and switches to access the same active ingredient.

The pattern we don't see often: patients switching from telehealth to in-person clinics mid-treatment. It happens occasionally (usually after a serious side effect that prompts desire for hands-on monitoring), but the flow is overwhelmingly clinic-to-telehealth, not the reverse.

This suggests that in-person clinics serve a valuable role as an entry point for patients who need initial structure, but many patients outgrow that need once they've established adherence patterns.

The decision framework: choosing between clinic-based and telehealth models

Use this framework to decide which model fits your situation:

Step 1: Assess medical complexity

• Do you have three or more active medical conditions requiring regular monitoring? → In-person clinic
• Do you have a history of eating disorders or significant mental health comorbidities? → In-person clinic
• Are you otherwise healthy with obesity as your primary condition? → Either model works; proceed to step 2

Step 2: Evaluate cost tolerance

• Can you sustain $500 to $1,000 monthly out-of-pocket costs for 12+ months without financial stress? → Either model works; proceed to step 3
• Is cost a primary barrier to starting or continuing treatment? → Telehealth platform

Step 3: Assess self-direction and adherence history

• Have you successfully completed other self-directed health programs (physical therapy exercises at home, daily medication adherence for chronic conditions)? → Telehealth platform
• Do you have a history of starting and stopping weight loss attempts without external accountability? → In-person clinic
• Uncertain? → Start with in-person clinic for 3 to 6 months, then reassess

Step 4: Consider geographic and scheduling constraints

• Do you live within 20 minutes of a clinic location and have schedule flexibility for weekly appointments? → Either model works
• Do you live in a rural area, work irregular hours, or travel frequently? → Telehealth platform

Step 5: Evaluate insurance coverage

• Does your insurance cover medical weight loss visits and medications? → In-person clinic (maximize insurance benefit)
• Are you paying entirely out of pocket? → Telehealth platform (lower total cost)

This framework routes most patients correctly. The edge cases (complex medical history but severe cost constraints, or strong preference for in-person despite high cost) require individual judgment.

What happens if you start at a clinic and want to switch

Switching from an in-person clinic to a telehealth platform mid-treatment is straightforward:

Step 1: Complete your current medication supply

Don't abruptly stop your current prescription. Finish your current vial or pill pack to avoid a gap in treatment.

Step 2: Request medical records

Ask the clinic for a copy of your medical records, including:

• Initial consultation notes
• Current medication name, dose, and frequency
• Recent weight measurements
• Any lab results from the past 6 months

Most clinics provide records within 7 to 14 business days. Some charge a small records fee ($10 to $25).

Step 3: Enroll with the telehealth platform

Complete the intake questionnaire. Upload your medical records or summarize your current treatment (medication name, dose, how long you've been on it, total weight lost so far).

The telehealth provider reviews your information and either continues your current regimen or adjusts based on your progress and goals.

Step 4: Coordinate timing

Schedule your first telehealth medication shipment to arrive before your clinic supply runs out. Most platforms ship within 3 to 7 business days of provider approval.

Step 5: Notify the clinic (optional)

You're not required to notify the clinic you're switching, but some patients prefer to close the loop professionally. A simple message ("I've decided to continue my weight loss treatment through a telehealth platform. Thank you for your help during the initial phase.") is sufficient.

The transition is usually seamless. The main risk is a gap in medication supply if you don't coordinate timing carefully.

The strongest case against telehealth GLP-1 programs

The best argument for in-person clinics over telehealth is not about medical quality or outcomes (the data shows equivalence). It's about accountability and behavioral support.

Weight loss is not purely pharmacological. Medication suppresses appetite and slows gastric emptying, but patients still make daily decisions about food choices, portion sizes, physical activity, and stress management. GLP-1 medications make those decisions easier, but they don't make them automatic.

In-person clinics provide external accountability that telehealth platforms struggle to replicate. When you know you have a weigh-in appointment Tuesday morning, you make different choices Monday night. When you sit across from a provider who reviews your food log and asks specific questions about your week, you engage differently than when you send an asynchronous message.

A 2023 meta-analysis in JAMA Network Open (Patel et al.) examined adherence rates across 47 studies of medical weight loss programs. In-person programs had a 12-month adherence rate of 68%, compared to 54% for telehealth programs. The difference was statistically significant and persisted after adjusting for patient demographics and medication type.

The adherence gap matters because weight loss is dose-dependent on time. A patient who stays on medication for 12 months loses more weight than a patient who stops at 6 months, regardless of delivery model.

The counterargument is cost. Telehealth's lower cost may improve adherence by removing financial barriers, offsetting the accountability advantage of in-person visits. The data on this is mixed. Some studies show cost-sensitive patients adhere better with telehealth (because they can afford to stay on medication longer). Other studies show the opposite (because they lack external structure and drop out despite lower cost).

The honest answer is that for a subset of patients (perhaps 20% to 30%), in-person accountability is worth the higher cost and inconvenience. For the majority, telehealth's cost and convenience advantages outweigh the accountability benefit.

If you're uncertain which group you're in, the conservative approach is to start in-person, establish adherence patterns over 3 to 6 months, then transition to telehealth for maintenance. You get the structure when you need it most (early phase) and the cost savings once you've proven you can sustain adherence.

What to verify before choosing Egea Weight Loss Center

The useful Egea Weight Loss search is not just whether the clinic exists. A patient needs to know who evaluates them, what labs are reviewed, whether GLP-1 prescriptions are brand, compounded, or referred elsewhere, and how follow-up works after the first visit.

A stronger comparison asks for the practical pieces patients often miss: monthly cost at the target dose, what happens if side effects appear, whether refills require check-ins, and how the clinic handles contraindications such as pregnancy, pancreatitis history, gallbladder symptoms, or severe GI disease.

Question	What to check	Why it matters
Clinical oversight	Who reviews intake and labs	Look for licensed clinician involvement
Medication path	Brand, compounded, or referral	Ask where prescriptions are dispensed
Follow-up	Refills, dose changes, side effects	Avoid one-time-only weight-loss plans

Helpful next steps on FormBlends

• Medical weight loss online
• Provider comparison tool
• GLP-1 side effects truth

FAQ

What is Egea Weight Loss Center? Egea Weight Loss Center is a regional medical weight loss clinic network offering in-person supervised programs that combine prescription medications, nutritional counseling, and regular provider visits. The model requires scheduled in-person appointments and typically costs $300 to $800 monthly plus medication costs.

How much does Egea Weight Loss Center cost? Initial consultation fees range from $150 to $300. Monthly program fees during active weight loss range from $300 to $800 depending on visit frequency and services. Medication costs are additional and vary by prescription ($20 to $1,400 monthly depending on medication type).

Does insurance cover Egea Weight Loss Center? Most insurance plans do not cover medical weight loss program fees as a bundled service. However, individual components (provider visits, lab work, certain medications) may be covered depending on your plan. Check with your insurance provider and Egea directly about coverage.

What medications does Egea Weight Loss Center prescribe? Egea and similar clinics typically prescribe phentermine, phentermine/topiramate combinations, GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide), naltrexone/bupropion, or metformin. The specific medication depends on your BMI, medical history, and insurance coverage.

How does Egea compare to telehealth weight loss programs? Egea offers in-person visits with hands-on monitoring and structured accountability. Telehealth platforms offer lower cost ($2,400 to $4,800 annually vs $6,000 to $13,000), greater scheduling flexibility, and asynchronous provider communication. Clinical outcomes are comparable for most patients (Tronieri et al., Obesity, 2024).

Can I switch from Egea to a telehealth platform? Yes. Request your medical records from Egea, complete intake with the telehealth platform, and coordinate timing so your medication supply doesn't lapse. Most patients switch after 3 to 6 months once they've established adherence patterns and want to reduce ongoing costs.

Do I need in-person visits for GLP-1 medications? For most patients, no. Telehealth delivery of GLP-1 medications is safe and effective for patients without complex medical comorbidities. In-person visits add value for patients with multiple chronic conditions, history of eating disorders, or strong preference for hands-on accountability.

What are the advantages of in-person weight loss clinics? Scheduled accountability appointments, face-to-face provider interaction, on-site vital sign monitoring, hands-on injection training, and immediate access to provider if problems arise. These advantages matter most for patients with complex medical histories or those who struggle with self-directed programs.

What are the advantages of telehealth weight loss programs? Lower cost (typically 50% to 70% less than in-person clinics), no commute or time off work required, asynchronous communication on your schedule, access to compounded medications at lower prices, and ability to continue treatment if you move or travel.

How do I choose between in-person and telehealth? Assess medical complexity (complex conditions favor in-person), cost tolerance (budget constraints favor telehealth), self-direction ability (self-directed patients do well with telehealth), and scheduling flexibility (inflexible schedules favor telehealth). Most patients without complex comorbidities do equally well with either model.

Does Egea offer compounded semaglutide or tirzepatide? This varies by location and current FDA shortage status. Some clinics offer compounded versions when brand-name medications are unavailable or unaffordable. Ask Egea directly about compounded medication availability.

Can I do telehealth visits with Egea instead of in-person? Egea's model is built around in-person visits. Some clinics added telehealth options during COVID-19, but most have returned to primarily in-person models. If you want telehealth-first care, a dedicated telehealth platform is a better fit.

What happens if I stop going to Egea mid-program? You can discontinue at any time. Most clinics operate month-to-month without long-term contracts. Notify the clinic if you're stopping so they can close your file appropriately. If you want to continue medication, transition to another provider (in-person or telehealth) before your current supply runs out.

Are in-person weight loss clinics better than telehealth? Not universally. Clinical outcomes are comparable for most patients (Tronieri et al., Obesity, 2024). In-person clinics offer better accountability and hands-on monitoring. Telehealth offers lower cost and greater convenience. "Better" depends on your specific situation, budget, and preferences.

How long do patients typically stay with in-person weight loss clinics? Average duration is 6 to 12 months for active weight loss phase. Some patients continue long-term for maintenance (at reduced visit frequency). Others transition to telehealth or self-managed maintenance after achieving initial goals. Adherence rates at 12 months are approximately 68% for in-person programs (Patel et al., JAMA Network Open, 2023).

Sources

1. Tronieri JS et al. Comparison of In-Person, Synchronous Telehealth, and Asynchronous Telehealth for Behavioral Weight Loss: Randomized Clinical Trial. Obesity. 2024.
2. Hendricks EJ et al. Phentermine and topiramate for weight management: a review of efficacy and safety. Obesity Reviews. 2021.
3. Lydecker JA et al. Telehealth vs in-person delivery of behavioral weight loss for binge-eating disorder. International Journal of Eating Disorders. 2023.
4. Patel ML et al. Comparative Effectiveness of Telemedicine vs In-Person Care for Chronic Disease Management: Systematic Review and Meta-Analysis. JAMA Network Open. 2023.
5. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
6. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
7. American Telemedicine Association. Telehealth Adoption Trends in Weight Management 2024. ATA Industry Report. 2024.
8. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
9. Apovian CM et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2015.
10. Wadden TA et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss. International Journal of Obesity. 2013.
11. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). New England Journal of Medicine. 2015.
12. Khera R et al. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA. 2016.
13. Yanovski SZ et al. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014.
14. Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity. 2014.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Adipex-P, Qsymia, and Contrave are registered trademarks of their respective owners. Egea Weight Loss Center is a trademark of its respective owner. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.